SeaStar Medical Holding Corp — SEC Form D Filing

SeaStar Medical Holding Corp filed an SEC Form D on October 8, 2026, reporting $3.30M raised in Other Health Care.

Form D filing details

Filing
SEC Form D
Filing date
October 8, 2026
Amount reported
$3.30M
Round stage
Growth funding raised via private placement to support the commercial deployment of its approved pediatric therapy and advance adult clinical trials.
Industry
Other Health Care
Website
https://seastarmedical.com

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Hyperinflammation and dysregulated immune responses in critically ill patients cause severe organ failure and high mortality rates during acute kidney injury.

Solution

SeaStar Medical Holding develops the Selective Cytopheretic Device to selectively neutralize hyperactive inflammatory cells in extracorporeal blood circuits during continuous renal replacement therapy.

Why now

Recent FDA approval of QUELIMMUNE for pediatric acute kidney injury creates an immediate commercialization opportunity for targeted immunomodulatory critical care devices.

Source: SEC EDGAR Form D filing